



LASA SUPERGENERICS LIMITED

CORPORATE OFFICE: B/207, City Point, Near Kohinoor Hotel, J B Nagar (Chakala)
Metro Station, Andheri (E), Mumbai – 400059, Maharashtra, India.
Tel: 022-4970 1092, Email: mail@lasalabs.com, Website: www.lasalabs.com

Statement of Unaudited Financial Results for the Quarter / Nine Months Period ended 31st December, 2017

Particulars	Quarter ended		Nine Months Ended
	31.12.2017 (Unaudited)	30.09.2017 (Unaudited)	31.12.2017 (Unaudited)
1. INCOME			
a. Revenue from Operations	6,098.61	6,453.07	18,652.70
b. Other Income	20.03	135.21	285.11
Total Income	6,118.64	6,588.28	18,937.81
2. Expenses			
a. Cost of Materials consumed	3,436.60	5,209.43	11,801.77
b. Change in Inventories of Finished Goods, Work-in-Progress and Stock in trade	629.63	(938.45)	226.52
c. Excise Duty on Sales	-	-	231.29
d. Employee benefits expenses	259.93	256.82	754.23
e. Finance costs	377.22	242.19	872.80
f. Depreciation & amortizations expenses	440.71	609.11	1,291.34
g. Other Expenses	424.10	621.65	1,456.18
Total Expenses (a to g)	5,568.18	6,000.75	16,634.12
Exceptional Items	-	-	-
3. Profit / (Loss) before tax (1-2)	550.46	587.54	2,303.69
4. Tax expense			
Current Tax	147.86	119.58	509.76
Deferred Tax	91.20	(398.42)	(89.10)
Short income tax provision for earlier years	-	-	1.73
5. Net Profit / (Loss) after tax (3-4)	311.40	866.37	1,881.31
6. Other Comprehensive Income			
<i>Items that will not be reclassified into Profit or Loss</i>			
Remeasurement of Defined Benefit Plans (Net of tax)	(0.22)	(0.36)	(1.32)
7. Total Comprehensive Income for the year (after tax) (5+6)	311.19	866.01	1,879.99
8. Paid-up Equity Share Capital (Face Value of Re. 10/- each)	2,286.44	2,286.44	2,286.44
9. Earnings per Equity Share (of Rs. 10/- each)			
(a) Basic	1.36	3.79	8.23
(b) Diluted	1.36	3.79	8.23
See accompanying Notes to the Financial Results			

Notes :

- 1) The Standalone Unaudited Financial Results for the Quarter and Nine Months ended 31st December, 2017, were reviewed by the audit committee and approved by the board of directors in their respective meetings held on 12th February, 2018. The Statutory Auditors of the company have reviewed the said Results.
- 2) The Financial Results are prepared in compliance with Indian Accounting Standards (Ind-AS) subsequent to its adoption as prescribed under Section 133 of the Companies Act, 2013 read with Rule 3 of the Companies (Indian Accounting Standards) Rules, 2015 and Companies (Indian Accounting Standards) Amendment Rules, 2016. These restated results have not been subjected to Limited Review, however, the Management has exercised due diligence to ensure that the Financial Results present a true and fair view of its affairs.
- 3) The above Financial Results which are published in accordance with Regulation 33 of the Securities and Exchange
- 4) The Statutory Auditors of the Company have carried out a "Limited Review" of the above Financial Results for the
- 5) The Company has only one reportable segment i.e. Veterinary Active Pharmaceutical Ingredients.
- 6) The format of unaudited quarterly and nine months results as prescribed in SEBI's circular CIR/CFD/CMD/15/2015
- 9) Figures of previous period have been re-grouped / reclassified wherever necessary, to confirm to this period's

For Lasa Supergenerics Limited

Sd/-
Omkar Herlekar
Chairman & Managing Director
(DIN No. 01587154)

Place : Mumbai
Date : 12.02.2018

CIN:L24233MH2016PLC274202

FACTORY & REGD. OFFICE: Plot No. C-105, MIDC, Mahad, Dist. Raigad, Maharashtra, India. Tel: +91-2145-232101/ 232202